These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9208352)

  • 1. The pharmacologic approach to the treatment of obesity.
    Weiser M; Frishman WH; Michaelson MD; Abdeen MA
    J Clin Pharmacol; 1997 Jun; 37(6):453-73. PubMed ID: 9208352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine.
    Heal DJ; Aspley S; Prow MR; Jackson HC; Martin KF; Cheetham SC
    Int J Obes Relat Metab Disord; 1998 Aug; 22 Suppl 1():S18-28; discussion S29. PubMed ID: 9758240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice.
    Astrup A; Lundsgaard C
    Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 2():29-34. PubMed ID: 9792479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Sibutramine, an upcoming drug for weight loss acting on energy consumption and energy expenditure].
    Astrup A
    Acta Med Austriaca; 1998; 25(4-5):146-9. PubMed ID: 9879391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity.
    Ryan DH
    Endocrine; 2000 Oct; 13(2):193-9. PubMed ID: 11186220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A benefit-risk assessment of sibutramine in the management of obesity.
    Nisoli E; Carruba MO
    Drug Saf; 2003; 26(14):1027-48. PubMed ID: 14583064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current concepts in the pharmacological management of obesity.
    Carek PJ; Dickerson LM
    Drugs; 1999 Jun; 57(6):883-904. PubMed ID: 10400403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment.
    Van Gaal LF; Wauters MA; De Leeuw IH
    Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 2():35-40. PubMed ID: 9792480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity.
    Halford JC; Harrold JA; Lawton CL; Blundell JE
    Curr Drug Targets; 2005 Mar; 6(2):201-13. PubMed ID: 15777190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An approach to the development of drugs for appetite disorders.
    Morley JE
    Neuropsychobiology; 1989; 21(1):22-30. PubMed ID: 2573002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges in obesity management.
    Poston WS; Foreyt JP; Borrell L; Haddock CK
    South Med J; 1998 Aug; 91(8):710-20. PubMed ID: 9715214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-HT2C receptor modulation and the treatment of obesity.
    Bickerdike MJ; Vickers SP; Dourish CT
    Diabetes Obes Metab; 1999 Jul; 1(4):207-14. PubMed ID: 11228755
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug strategies for the treatment of obesity.
    Alemany M; Remesar X; Fernández-López JA
    IDrugs; 2003 Jun; 6(6):566-72. PubMed ID: 12811679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sibutramine: its mode of action and efficacy.
    Finer N
    Int J Obes Relat Metab Disord; 2002 Dec; 26 Suppl 4():S29-33. PubMed ID: 12457297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioural satiety sequence (BSS): separating wheat from chaff in the behavioural pharmacology of appetite.
    Rodgers RJ; Holch P; Tallett AJ
    Pharmacol Biochem Behav; 2010 Nov; 97(1):3-14. PubMed ID: 20214921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The discovery and status of sibutramine as an anti-obesity drug.
    Luque CA; Rey JA
    Eur J Pharmacol; 2002 Apr; 440(2-3):119-28. PubMed ID: 12007530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug therapy for obesity in the elderly.
    Dvorak R; Starling RD; Callés-Escandon J; Sims EA; Poehlman ET
    Drugs Aging; 1997 Nov; 11(5):338-51. PubMed ID: 9359021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy of obesity: an update.
    Schurgin S; Siegel RD
    Nutr Clin Care; 2003; 6(1):27-37. PubMed ID: 12841428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sibutramine--a review of clinical efficacy.
    Lean ME
    Int J Obes Relat Metab Disord; 1997 Mar; 21 Suppl 1():S30-6; discussion 37-9. PubMed ID: 9130039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.